Search Results
Your search for The ASCO Post ,The ASCO Post matches 17363 pages
Showing 1651 - 1700Four Novel Biomarkers May Help Detect Black Patients at Risk of Advanced Prostate Cancer
Researchers have identified a cell metabolism process found in male patients with West African ancestry who have diabetes and metastatic prostate cancer that could potentially lead to improved testing and treatments for Black patients with both diseases. The findings by Shuck et al were presented...
Diagnosing Early-Stage Bladder Cancer in Patients With Hematuria: Novel mePENK Test
Researchers have found that the new PENK methylation (mePENK) test could potentially pave the way for a breakthrough in early bladder cancer detection in patients with hematuria, according to a novel study published by Oh et al in The Journal of Molecular Diagnostics. The findings could reduce the...
PSMA PET/CT Imaging May Eliminate the Need for Preimaging Biopsy in Older Patients Undergoing Screening for Prostate Cancer
Prostate-specific membrane antigen positron-emission tomography/computed tomography (PSMA PET/CT) imaging may help physicians diagnose advanced disease and select the appropriate therapeutic interventions in patients aged 80 years or older with suspected prostate cancer, according to a recent study ...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus cabozantinib vs the former standard-of-care sunitinib as first-line treatment of advanced or metastatic renal cell carcinoma.1 These benefits were achieved with the...
FDA Approves Melphalan Hepatic Delivery System for Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
On August 14, the U.S. Food and Drug Administration (FDA) approved the HEPZATO KIT, a melphalan hepatic delivery system, as a liver-directed treatment for adult patients with metastatic uveal melanoma and unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic...
Accelerated Approval for Elranatamab-bcmm in Patients With Relapsed or Refractory Multiple Myeloma
On August 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elranatamab-bcmm (Elrexfio), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior...
Recent FDA Approvals in Hematologic Oncology
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in hematologic oncology. Glofitamab for DLBCL On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm (Columvi) for...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
Expert Point of View: Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Expert Point of View: Catherine S. Diefenbach, MD
Catherine S. Diefenbach, MD, Associate Professor at NYU Grossman School of Medicine, Director of the Clinical Lymphoma Program, and Director of Hematology Translational Research at Perlmutter Cancer Center, in New York, called the findings from the TRANSFORM trial “very striking.” “This study...
Expert Point of View: Julio Chavez, MD
Julio Chavez, MD, a hematologist at Moffitt Cancer Center, Tampa, Florida, commented on the updated results from the MAGNOLIA trial. “MAGNOLIA was a phase II trial that included patients with marginal zone lymphoma after one or more prior lines of therapy. At the ASH meeting, we heard updated...
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
Expert Point of View: Caron Jacobson, MD
Caron Jacobson, MD, shared some comments on ZUMA-7 with The ASCO Post. She called ZUMA-7 “an extremely important study to advance the care of high-risk early relapsing or primary refractory large B-cell lymphoma after front-line chemoimmunotherapy.” Dr. Jacobson is Assistant Professor of Medicine...
T-Cell Tolerant Fraction May Predict Immune-Related Adverse Events Among Patients Receiving Immunotherapy
Researchers have identified a novel parameter of T cells that may help oncologists anticipate which patients are most likely to develop immunotherapy toxicity. The findings, published by Ostmeyer in the Journal for ImmunoTherapy of Cancer, could lead to improved treatments for a variety of ...
Are Immune Checkpoint Inhibitors Efficacious Among Patients With Penile Squamous Cell Carcinoma?
Penile squamous cell carcinoma is a rare type of penile cancer with limited treatment options. An international study has found that the use of immune checkpoint inhibitors may offer clinical benefits for some patients with advanced penile squamous cell carcinoma. These findings were published by...
FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On August 11, the U.S. Food and Drug Administration (FDA) approved the fixed-dose combination of niraparib and abiraterone acetate (Akeega), with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by...
AI-Driven Muscle Mass Assessment May Aid in Detecting Sarcopenia in Patients With Head and Neck Cancer
Researchers have found a way to use artificial intelligence (AI) to diagnose sarcopenia in patients with head and neck cancer. The tool may be used to improve treatment and supportive care for patients, according to a report published by Ye et al in JAMA Network Open. “Sarcopenia is an indicator...
FDA Approves Pralsetinib for RET Fusion–Positive NSCLC
On August 9, the U.S. Food and Drug Administration (FDA) granted regular approval to pralsetinib (Gavreto) for adults with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. ARROW Trial Pralsetinib was previously granted accelerated approval for...
FDA Grants Accelerated Approval to Talquetamab-tgvs for Treatment of Relapsed or Refractory Multiple Myeloma
On August 9, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the bispecific antibody talquetamab-tgvs (Talvey) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including a proteasome inhibitor, an...
American Society for Radiation Oncology Names Newly Elected Officers to Board of Directors
The members of the American Society for Radiation Oncology (ASTRO) recently elected three new officers to ASTRO’s Board of Directors: Sameer Keole, MD, FASTRO, as President-Elect; Wendy Woodward, MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S. Kavadi, MD, MBA, FASTRO, as Health Policy...
Overcoming Financial Toxicity From Cancer
I knew the moment my fingers found a lump in my left breast, in 2018, that it was cancer, and I wondered if I was going to die. My maternal grandmother had been diagnosed with breast cancer when she was 39, the same age I was when I discovered the mass in my breast. She died 5 years later. Divorced ...
CAR T-Cell Therapies: Trends and Indications
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. With this installment, we launch a new series of articles on commercially available chimeric antigen receptor (CAR) T-cell therapies. Syed Ali Abutalib, MD, and Jennifer N. ...
Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin
Nigel Russell, MD, of Guy’s and St. Thomas’ NHS Foundation Trust, discusses the latest results from the AML19 trial, which showed the chemotherapy regimen FLAG-Ida (fludarabine, high-dose cytarabine, idarubicin, and granulocyte-colony stimulating factor), when combined with gemtuzumab ozogamicin,...
Alcohol Consumption and Risk of Breast Cancer Recurrence
A report published by Kwan et al in the journal Cancer provides new information that may help oncologists answer one of the most common questions they hear from breast cancer survivors: Is it safe to drink alcohol? The findings suggest drinking alcohol is not associated with an increased risk of...
Does Daily Consumption of Sugar-Sweetened Beverages Increase the Risk of Liver Disease Among Postmenopausal Women?
Approximately 65% of adults in the United States consume sugar-sweetened beverages daily. Researchers led a study examining the associations among intake of sugar-sweetened or artificially sweetened beverages and the incidence of liver cancer and chronic liver disease mortality in a large cohort of ...
Elevated MRI Enhancement May Indicate Increased Risk of Cancer in Patients With Very Dense Breasts
A machine-learning model found that background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) may be an indicator of breast cancer risk in patients with extremely dense breasts, according to a study published by Wang et al in Radiology. Patients with extremely dense...
New World Economic Forum Research Identifies Top AI Applications That Could Revolutionize Global Health Care
A new World Economic Forum report released June 26, 2023, highlights the transformative potential of artificial intelligence (AI) in health care and the importance of public-private collaboration in driving its global adoption.1 The report—“Scaling Smart Solutions With AI in Health: Unlocking...
On the Art of Organizing Best of ASCO Meetings
Preparing and running a medical conference is usually a complex but rewarding mission. It is a demanding job that is typically done voluntarily by physicians and educators who are dedicated to professional and community service; advancement of research and education; as well as the dissemination of ...
How Multidisciplinary Specialties Are Coming Together to Improve the Quality of Life of Cancer Survivors
As we detailed in our Special Report “Surviving, but Not Always Thriving, After Cancer,” in the May 25, 2023, issue of The ASCO Post, the combination of advances in more effective therapies to treat cancer, gains in early detection, and sharp declines in tobacco use have led to a staggering 33%...
Fine Particulate Matter Exposure May Increase Risk of Primary Cancers Other Than Lung Cancer
Chronic exposure to fine particulate air pollutants (PM2.5, particulate matter 2.5 µm in diameter) and nitrogen dioxide (NO2) may increase non-lung cancer risk in older adults, according to a study published by Yaguang et al in Environmental Epidemiology. In a cohort study of millions of Medicare...
Report Highlights Rapid Adoption of Clinical Research Results Into Colon Cancer Chemotherapy Prescribing Patterns
New research published by Ou et al in JNCCN—Journal of the National Comprehensive Cancer Network evaluated how an important analysis on adjuvant chemotherapy for advanced colon cancer impacted prescribing patterns. The IDEA collaboration included more than 12,000 patients with stage III colon...
Study Shows Substantial Racial and Ethnic Disparities Among Survivors of Second Primary Cancers in the United States
In a new study published by Hyuna Sung, PhD, and colleagues in JAMA Network Open, non-Hispanic Black individuals diagnosed with a second primary cancer experienced 21% higher cancer-related death rates and 41% higher cardiovascular-related death rates compared with non-Hispanic White individuals;...
Translating Consent Documents: Potential Barrier for Including Underrepresented Groups in Clinical Trials
Cancer research centers conducting clinical trials could potentially enroll more patients from underrepresented racial and ethnic groups by placing a greater emphasis on relieving investigators of the costs of translating consent documents into languages other than English, according to a study...
Analysis Challenges Theory That Depression and Anxiety May Increase Cancer Risk
Experts have suspected that depression and anxiety may increase cancer risk by affecting a person’s health-related behaviors or by having biological effects on the body that support cancer development. Some research has supported an association among depression, anxiety, and cancer incidence,...
How Does BMI Affect Cardiac Health for Patients With Breast Cancer Receiving Chemotherapy?
A study covering the northeast region of Colombia found nearly 12% of patients with a high body mass index (BMI) being treated for breast cancer at a regional center experienced cardiotoxicity during chemotherapy. The study will be presented at the upcoming American College of Cardiology Latin...
Wildfire Exposure and Survival Outcomes After Surgery for NSCLC
Investigators have found that exposure to wildfires within 1 year of surgery may significantly lower the chance of survival in patients with non–small cell lung cancer (NSCLC), according to a recent study published by Zhang et al in JAMA Oncology. Background Lung cancer is the second most common...
Comparison of Outcomes of Surgical vs Nonsurgical Approaches in Patients With Malignant Bowel Obstructions
Researchers have compared the efficacy of surgical and nonsurgical interventions for patients with malignant bowel obstructions, according to a recent study published by Krouse et al in The Lancet Gastroenterology & Hepatology. The new findings may help to inform clinical decision-making in the ...
Early-Stage Cancer Diagnoses in the United States May Have Decreased During the First Year of the COVID-19 Pandemic
Investigators have found that monthly U.S. adult cancer diagnoses decreased by 50% early in April 2020 and that the largest decreases were observed for stage I tumors, resulting in a higher proportion of late-stage cancer diagnoses, according to a recent study published by Han et al in The Lancet...
ACP Issues Updated Clinical Guidelines for Screening Asymptomatic, Average-Risk Adults for Colorectal Cancer
The American College of Physicians (ACP) suggested screening asymptomatic, average-risk adults for colorectal cancer at age 50 years, according to updated clinical guidelines published by Qaseem et al in the Annals of Internal Medicine. New ACP Clinical Guidelines Colorectal cancer has the fourth...
FDA Approves Trifluridine and Tipiracil With Bevacizumab for Previously Treated Metastatic Colorectal Cancer
On August 2, the U.S. Food and Drug Administration (FDA) approved trifluridine and tipiracil (Lonsurf) with bevacizumab for patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if ...
Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors
About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent study published by Han et al in PLOS ONE. Background While depression, anxiety, and fatigue are...
Researchers Characterize Adverse Immune Events in Patients With Cancer Who Experience Immune Checkpoint Inhibitor–Associated Arthritis
Researchers may have uncovered the immune adverse events and the specific type of CD8 T cells that characterize inflammatory arthritis induced by immune checkpoint inhibitors, according to a recent study published by Wang et al in Science Immunology. Immune checkpoint inhibitors used to treat...
Expert Point of View: Joshua Zeidner, MD
Joshua Zeidner, MD, Associate Professor of Medicine, Chief of Leukemia Research, and Associate Chief of Hematology Research at the University of North Carolina Lineberger Comprehensive Cancer Center, emphasized the high risk of relapse, even after allogeneic stem cell transplantation, for patients ...
Researchers May Have Uncovered Two New Subtypes of HPV-Positive Head and Neck Squamous Cell Carcinomas
Human papillomavirus (HPV)–positive head and neck squamous cell carcinomas can be divided into two distinct subtypes that may help determine how well patients will respond to therapy, according to a novel study published by Schrank et al in PNAS. The findings also identified a new mechanism of HPV...
Can an AI-Based Tool Accurately Detect Precancerous Cervical Lesions?
Researchers in Japan have developed an artificial intelligence (AI)-based diagnostic tool for colposcopy examinations that may accurately identify cervical intraepithelial neoplasia (CIN) and subsequently suggest appropriate biopsy sites. The research will be presented by Ueda et al at the 2023...
Exercise May Reduce Sexual Dysfunction Caused by Prostate Cancer Treatment
A combination of resistance and aerobic exercise may improve sexual function in patients with prostate cancer, according to a new study conducted in Australia. The research was presented by Galvao et al at the 2023 ASCO Breakthrough meeting (Abstract 71) in Yokohama, Japan. “Sexual dysfunction is a ...
